| abstract |
The present disclosure provides a treatment for diabetes that targets aberrant stem cells. In one embodiment, the present disclosure provides for the treatment of diabetes and/or diseases, disorders and/or conditions associated with diabetes that target aberrant stem cells. In one embodiment, the present disclosure provides diagnosis of diabetes and/or diabetes-related diseases, disorders and/or symptoms, or risk thereof using abnormal stem cells as an index. In one embodiment, the aberrant stem cell of the present disclosure is an aberrant hematopoietic stem cell. In one embodiment, the aberrant stem cells of the present disclosure express CD106 at a level different from that of normal cells. |